Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2007

View Archived Issues

Recent patents cover new therapeutic agents for cancer

Novel treatments for musculoskeletal and connective tissue disorders claimed in recent patents

Recent Schering and Epix patents disclose novel MRI agents

Novel treatment options for gastrointestinal disorders reported in recent patents

Phase IIa study of oleoyl-estrone for obesity completes enrollment

Identification of active sites of Polo-like kinases useful for developing new cancer therapies

Access to acquire Somanta

GCN2 critical for regulating fat metabolism during essential amino acid deprivation

Apollo Life Sciences reduces inflammation with oral TNF blocker

Dyax and Genzyme end DX-88 joint venture

IAVI applauds creation of Canadian HIV Vaccine Initiative

Avax collaborates with CTCA on O-Vax vaccine

AlphaRx's nanoparticle drug delivery system shows potential in tuberculosis

GPC Biotech launches satraplatin expanded access program

TransTech licenses Novo Nordisk's GKA program

Hybrigenics focuses research on USP inhibitors for cancer

DiaKine licenses cytokine modulators from U. of Virginia

Orphan drug status awarded to rhPDGF-BB for osteonecrosis of the jaw

Pharmacyclics receives refusal to file letter for Xcytrin

Avastin plus chemotherapy improves PFS in advanced NSCLC patients

Indena patents novel compounds for treating skeletal muscle spasms

Fosrenol launched in U.K.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...